title: Reduced Leaflet Motion in Bioprosthetic Aortic Valves--The FDA Perspective.
authors.affiliation: From the Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD.
authors.forename: John C
authors.initials: JC
authors.lastname: Laschinger
authors.forename: Changfu
authors.initials: C
authors.lastname: Wu
authors.forename: Nicole G
authors.initials: NG
authors.lastname: Ibrahim
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Shuren
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001021:Aortic Valve / Q000503:physiopathology*; D001705:Bioprosthesis / Q000009:adverse effects*; D005260:Female; D006349:Heart Valve Diseases / Q000209:etiology*; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D013927:Thrombosis / Q000209:etiology*
chemical_list: D000925:Anticoagulants